|
Prevalence of ALK mutations in advanced NSCLC patients in the United States: Analysis with a real world oncology database. |
|
|
Consulting or Advisory Role - Merck |
|
|
Employment - Roche Molecular Diagnostics |
Stock and Other Ownership Interests - Roche Molecular Diagnostics |
Travel, Accommodations, Expenses - Roche Molecular Diagnostics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - AstraZeneca/MedImmune; Roche Molecular Diagnostics |
Stock and Other Ownership Interests - Roche |
|
|
|
Travel, Accommodations, Expenses - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
Travel, Accommodations, Expenses - Roche |
|
|
Employment - Roche Molecular Diagnostics |
Stock and Other Ownership Interests - Roche |
Research Funding - Roche Molecular Diagnostics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Guardant Health; Pfizer |
Research Funding - EMD Serono |